Pershing Square seeks declaratory statement re Allergan poison pill

Bill Ackman's Pershing Square Capital Management L.P., files a lawsuit in the Delaware Court of Chancery seeking a declaratory statement that its actions to call a special meeting of shareholders will not trigger Allergan's (AGN) poison pill provision. Mr. Ackman filed the suit after AGN failed to confirm his June 6 written request that it would not invoke its poison pill.

Related ticker: (VRX)

From other sites
Comments (3)
  • Retail Investor
    , contributor
    Comments (823) | Send Message
    Great shareholder activism.
    13 Jun 2014, 07:19 AM Reply Like
    , contributor
    Comments (4) | Send Message
    13 Jun 2014, 11:02 AM Reply Like
  • fjm1058
    , contributor
    Comments (6) | Send Message
    Question - do you really want the offer now that VRX stock has shown volatility that could sway the price of the offer as low as $170/share? Based on the information available and the stench of desperation from VRX to get the deal done before the B&L numbers get released, aren't you at all skeptical about the deal?


    As a long time AGN investor I believe in the long term viability of their strategic plan and potential for growth and am happy to continue to say "NO" to VRX and their hostile bid. Maybe I would feel differently if AGN was mismanaged or underperforming; but they are not and continually have been a shining piece of my portfolio.


    Just wanted to hear your thoughts. Thanks
    13 Jun 2014, 02:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs